MISMATCH REPAIR DEFICIENT COLORECTAL CANCER

Clinical trials for MISMATCH REPAIR DEFICIENT COLORECTAL CANCER explained in plain language.

Never miss a new study

Get alerted when new MISMATCH REPAIR DEFICIENT COLORECTAL CANCER trials appear

Sign up with your email to follow new studies for MISMATCH REPAIR DEFICIENT COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Completed 1

Immunotherapy trial shows promise for shrinking advanced colon tumors

Disease control Completed

This completed Phase 2 trial tested whether the immunotherapy drug nivolumab, either alone or combined with other cancer drugs, could meaningfully shrink tumors in people with advanced colon cancer that had returned or spread. The study enrolled 385 participants whose tumors had …

Matched conditions: MISMATCH REPAIR DEFICIENT COLORECTAL CANCER

Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control

Last updated Mar 17, 2026 13:09 UTC

MISMATCH REPAIR DEFICIENT COLORECTAL CANCER

Get alerted when new MISMATCH REPAIR DEFICIENT COLORECTAL CANCER trials appear

Immunotherapy trial shows promise for shrinking advanced colon tumors